Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A known ✓ | Q14432 | 2/20 | 0.50 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.44 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.95 |
| ▸ | CA9 | Q16790 | 5/20 | 0.95 |
| ▸ | CA1 | P00915 | 1/20 | 0.95 |
| ▸ | CA3 | P07451 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | CA5A | P35218 | 1/20 | 0.95 |
| ▸ | CA7 | P43166 | 1/20 | 0.95 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1239260 | 1.00 | CA12 (0.95) | CA12CA9CA1CA3CA4 | |
| Hydrochloric Acid SCHEMBL4429445 | 1.00 | CA12 (0.95) | CA12CA9CA1CA3CA4 | |
| Hydrochloric Acid SCHEMBL29388406 | 1.00 | CA12 (0.95) | CA12CA9CA1CA3CA4 | |
| Hydrochloric Acid SCHEMBL7181614 | 0.98 | CA12 (0.91) | CA12CA9CA1CA3CA4 | |
| Hydrochloric Acid SCHEMBL28247699 | 0.98 | CA12 (0.91) | CA12CA9CA1CA3CA4 | |
| SCHEMBL8621 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL30958273 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL29351086 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL5437282 | 0.98 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| Water SCHEMBL10661261 | 0.95 | CA12 (0.95) | CA12CA9CA1CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755963-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | claimed |
| CN-1660812-A | New medical salt and preparation in group of carbostyril mandelate and preparing method | LI JIE (CN) | 2005-08-31 | — | — | CN | claimed |
| EP-1546145-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004029048-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-08 | — | — | WO | claimed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | claimed |
| CN-116574105-A | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-110950842-B | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-109988093-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-112689628-A | Pesticidally active azole-amide compounds | 先正达参股股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| EP-3768675-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2021-01-27 | — | — | EP | disclosed |
| CN-110950842-A | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-1033752-C | (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives | JANSSEN PHARMACEUTICA NV (SE) | 1997-01-08 | — | — | CN | disclosed |
| WO-1993025545-A1 | NOVEL QUINOLINE DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-12-23 | — | — | WO | disclosed |
| EP-0574231-A1 | Quinolone and naphthyridine derivatives having at the 3-position a group other than a carboxy group, as antibacterials | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-12-15 | — | — | EP | disclosed |
| EP-0489379-A1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
| EP-0147719-A2 | Novel carbostyril derivative and process for preparing same | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-10 | — | — | EP | disclosed |